Before the first Pradaxa (dabigatran) product liability case went to trail, Boehringer Ingelheim Pharmaceuticals Inc. reached a comprehensive $650 million settlement of federal and state product liability suits.
In a May 28 release, the company said it seeks to resolve approximately 4,000 claims with the settlement and that it expects most, if not all, of the plaintiffs to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?